Diabetes therapeutics are undergoing one of the most important shifts in their history. The field is moving beyond glucose-lowering toward molecules that influence cardiovascular outcomes, immune pathways, and long-term metabolic health. Recent advances have introduced oral incretin therapies with outcome-level evidence, immune-modulating agents th